Table 2.
Active Ingredient | Average Size | Model Animals | Outcomes Offered by Nanoparticles | Reference |
---|---|---|---|---|
Paclitaxel | 2 nm | Rat | An increased bioavailability of 1.3–1.5-fold compared to Taxol® | Yang et al. [97] |
Paclitaxel | Unknown | Patients with cancers | A decreased tmax of 2-fold compared to Taxol® | Veltkamp et al. [99] |
Docetaxel | 160–180 nm | Rat | An increased bioavailability of 3.2-fold compared to Taxotere® | Valicherla et al. [100] |
Cyclosporine A | 72 nm | Rat | An increased bioavailability of 4.5-fold compared to Bioral® | Jain et al. [102] |
Sirolimus | 108 nm | Rat | An increased bioavailability of 1.3-fold compared to Rapamune® | Cho et al. [103] |
Cefpodoxime | 55–60 nm | Rat | An increased bioavailability of 5.4-fold compared to plain drug | Bajaj et al. [104] |
Fenofibrate | Unknown | Human | The bioavailability was reduced by SEDDSs | Wei et al. [106] |
Fenofibrate | 205–379 nm | Human | An increased bioavailability of 1.2-fold compared to Tricor® | Lin et al. [107] |
TPGS, d-α-tocopheryl polyethylene glycol succinate.